Trial · NCT00500890
Treatment of Tumors of the Choroid Plexus Epithelium
NCT00500890, Phase 3, Terminated, M.D. Anderson Cancer Center; results first posted 2020-02-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Tumors of the Choroid Plexus Epithelium. Trials, record NCT00500890. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00500890
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Tumors of the Choroid Plexus Epithelium
- NCT number
- NCT00500890
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 2 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Choroid Plexus Tumors
- Interventions
- Carboplatin, Cyclophosphamide, Etoposide, Vincristine, Radiation Therapy
- First posted
- 2007-07-13
- Last updated
- 2020-02-27
- Results first posted
- 2020-02-27
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Main Phase (Started in 2006) Primary Specific Objective | After randomization until the end of the observation or the death of the patient | To compare the survival times after cyclophosphamide based treatment with survival times after carboplatin based treatment in chroid plexus tumors patients. For analysis, there will be no difference between death by tumor progression, treatment related (toxic) reasons or unrelated reasons. |
| Primary | Secondary Objective SV40 | No data were collected due to early termination | To determine the prognostic relevance of histological atypia and SV40 in choroid plexus tumors. Prognosis of tumors with or without SV40 will be compared using overall survival time as endpoint. Kaplan Meier survival estimates and log rank tests as statistical methods similar to the analysis of primary objective. |
| Secondary | Secondary Objective Resectability | No data were collected due to early termination | To compare the resectability of choroid plexus tumors after two blocks of cyclophosphamide based therapy treatment with the resectability after two blocks of carboplatin based treatment. Success of surgery after first 2 cycles of chemotherapy will be compared between two treatment arms. Percentage of patients with secondary complete remission from those with incomplete primary resection, will be used to analyze question. Tumor with CR and tumors which could be completely resected after two cycles of chemotherapy will be counted together. Frequency will be compared a month the 2 treatment arms using Chi-square test. |
| Secondary | Secondary Objective Response | No data were collected due to early termination | To compare response rates of incompletely resected choroid plexus tumors to two blocks of cyclophosphamide based therapy treatment with the response rates after two blocks of carboplatin based treatment. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Main Phase (Started in 2006) Primary Specific Objective | After randomization until the end of the observation or the death of the patient | No data were collected due to early termination. | ||
| PRIMARY | Secondary Objective SV40 | No data were collected due to early termination | No data were collected due to early termination | ||
| SECONDARY | Secondary Objective Resectability | No data were collected due to early termination | No data were collected due to early termination. | ||
| SECONDARY | Secondary Objective Response | No data were collected due to early termination | No data were collected due to early termination |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Carboplatin + Etoposide + Vincristine | 1 | |
| Overall Study | STARTED | Cyclophosphamide + Etoposide + Vincristine | 1 | |
| Overall Study | COMPLETED | Carboplatin + Etoposide + Vincristine | 1 | |
| Overall Study | COMPLETED | Cyclophosphamide + Etoposide + Vincristine | 1 | |
| Overall Study | NOT COMPLETED | Carboplatin + Etoposide + Vincristine | 0 | |
| Overall Study | NOT COMPLETED | Cyclophosphamide + Etoposide + Vincristine | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Neutropenic Fever | Infections and infestations | Carboplatin + Etoposide + Vincristine | 0 | 1 | |
| serious | Neutropenic Fever | Infections and infestations | Cyclophosphamide + Etoposide + Vincristine | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Carboplatin + Etoposide + Vincristine | 0 | 1 |
| Total, all-cause mortality | Cyclophosphamide + Etoposide + Vincristine | 0 | 1 |
| Total, other adverse events | Carboplatin + Etoposide + Vincristine | 0 | 1 |
| Total, other adverse events | Cyclophosphamide + Etoposide + Vincristine | 0 | 1 |
| Total, serious adverse events | Carboplatin + Etoposide + Vincristine | 0 | 1 |
| Total, serious adverse events | Cyclophosphamide + Etoposide + Vincristine | 1 | 1 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 19543851 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Carboplatin + Etoposide + Vincristine vs Cyclophosphamide + Etoposide + Vincristine: deaths from any cause | Trial comparisons |
| Carboplatin + Etoposide + Vincristine vs Cyclophosphamide + Etoposide + Vincristine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00500890
GET https://conductscience.org/api/trials/v1/NCT00500890/registered